To overcome the industry bottleneck of few validated solid tumor targets (15-20), Memo analyzes tumor-infiltrating B-cells from patients with superior outcomes. This approach aims to identify unique antibody-target pairs, unlocking new biological pathways for next-generation therapies like ADCs and CAR-Ts.

The company focuses on disease-specific 3D protein conformations, which exposes new binding sites (epitopes) not present on the same protein in healthy cells. This allows for highly selective drugs that avoid the toxicity common with targets defined by genetic sequence alone.

By treating patients before their tumors are surgically removed, Infinitopes can analyze the resected tissue. This provides direct evidence of CD8 T cell infiltration in response to the vaccine—a powerful, mechanistic proof-point that is impossible for competitors testing in later-stage patients.

The most common investor misconception is that cancer vaccines have "never worked." The key rebuttal is that past failures targeted generic, shared antigens. The new generation of vaccines is fundamentally different, targeting specific mutations unique to each patient's tumor, which changes the entire paradigm.

The founding premise of Enara Bio was a forward-looking belief. As the T-cell engager field matured, they predicted a critical shortage of viable targets would emerge. By creating a platform to discover novel "dark antigens" from the non-coding genome, they positioned themselves to solve a problem before it became mainstream.

T-cell receptor (TCR) therapies offer a significant advantage over monoclonal antibodies by targeting intracellular proteins. They recognize peptides presented on the cell surface, effectively unlocking 90% of the proteome and requiring far fewer target molecules (5-10 copies vs. 1000+) to kill a cancer cell.

To overcome on-target, off-tumor toxicity, LabGenius designs antibodies that act like biological computers. These molecules "sample" the density of target receptors on a cell's surface and are engineered to activate and kill only when a specific threshold is met, distinguishing high-expression cancer cells from low-expression healthy cells.

Even though companies like Moderna (mRNA) and Transgene (viral vector) use different platforms, positive results from any of them help validate the entire individualized neoantigen approach for investors and clinicians. The massive unmet medical need ensures the market is large enough to support multiple successful players.

Unconventionally, Infinitopes' first-in-human trial targets neoadjuvant patients (newly diagnosed, pre-surgery). This provides cleaner efficacy signals compared to trials in heavily pre-treated patients and enables unique analysis of resected tumors to prove the vaccine's mechanism, a key differentiator from competitors.